Renaissance Technologies
RNAC icon

Renaissance Technologies’s Cartesian Therapeutics RNAC Stock Holding History

Renaissance Technologies’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Buy
67,300
+26,200
+64% +$187K ﹤0.01% 2676
2025
Q4 		$296K Buy
+41,100
New +$332K ﹤0.01% 2769
2025
Q3 		– Sell
-19,500
Closed -$203K – 3841
2025
Q2 		$203K Buy
+19,500
New +$208K ﹤0.01% 3169
2025
Q1 		– Sell
-13,800
Closed -$247K – 3776
2024
Q4 		$247K Buy
+13,800
New +$279K ﹤0.01% 3101
2024
Q3 		– Sell
-17,052
Closed -$461K – 3824
2024
Q2 		$461K Sell
17,052
-1,401
-8% -$33.4K ﹤0.01% 2730
2024
Q1 		$360K Buy
18,453
+1,193
+7% +$25.3K ﹤0.01% 3006
2023
Q4 		$357K Sell
17,260
-6,940
-29% -$207K ﹤0.01% 2913
2023
Q3 		$770K Sell
24,200
-9,217
-28% -$308K ﹤0.01% 2471
2023
Q2 		$1.12M Sell
33,417
-2,353
-7% -$84.2K ﹤0.01% 2395
2023
Q1 		$1.49M Sell
35,770
-5,059
-12% -$238K ﹤0.01% 2210
2022
Q4 		$1.38M Buy
40,829
+10,659
+35% +$453K ﹤0.01% 2325
2022
Q3 		$1.48M Buy
30,170
+10,557
+54% +$580K ﹤0.01% 2239
2022
Q2 		$771K Sell
19,613
-30,067
-61% -$891K ﹤0.01% 2877
2022
Q1 		$1.83M Buy
49,680
+33,807
+213% +$2.11M ﹤0.01% 2292
2021
Q4 		$1.55M Buy
15,873
+7,133
+82% +$767K ﹤0.01% 2350
2021
Q3 		$1.09M Sell
8,740
-5,535
-39% -$668K ﹤0.01% 2504
2021
Q2 		$1.79M Buy
14,275
+4,792
+51% +$571K ﹤0.01% 2330
2021
Q1 		$1.29M Sell
9,483
-22,891
-71% -$2.84M ﹤0.01% 2489
2020
Q4 		$2.94M Buy
32,374
+15,829
+96% +$1.37M ﹤0.01% 1906
2020
Q3 		$1.23M Sell
16,545
-21,360
-56% -$1.64M ﹤0.01% 2401
2020
Q2 		$3.23M Sell
37,905
-11,258
-23% -$1.02M ﹤0.01% 1894
2020
Q1 		$3.55M Buy
49,163
+20,021
+69% +$1.93M ﹤0.01% 1758
2019
Q4 		$2.08M Buy
29,142
+7,996
+38% +$386K ﹤0.01% 2307
2019
Q3 		$1.11M Buy
21,146
+5,429
+35% +$289K ﹤0.01% 2554
2019
Q2 		$844K Buy
15,717
+7,794
+98% +$531K ﹤0.01% 2768
2019
Q1 		$563K Buy
7,923
+4,200
+113% +$266K ﹤0.01% 2889
2018
Q4 		$297K Buy
3,723
+3,303
+786% +$754K ﹤0.01% 3027
2018
Q3 		$196K Buy
+420
New +$169K ﹤0.01% 3158

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies's RNAC Position: Q1 2026 in Review

Renaissance Technologies increased its Cartesian Therapeutics (RNAC) stake by 64% in Q1 2026, buying an estimated $187K and bringing the position to 67,300 shares worth $414K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

Renaissance Technologies first reported a position in RNAC in Q3 2018 and has held it in 28 quarters since. The position peaked at $3.55M in Q1 2020. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Renaissance Technologies held 67,300 shares of Cartesian Therapeutics worth $414K as of Q1 2026.
  • Renaissance Technologies bought 26,200 Cartesian Therapeutics shares in Q1 2026, an estimated $187K.
  • Cartesian Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2676 holding.
  • Renaissance Technologies first reported a position in Cartesian Therapeutics in Q3 2018 and has held it in 28 quarters since.
  • Renaissance Technologies's Cartesian Therapeutics position peaked at $3.55M in Q1 2020.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.